AAO '22: GATHER2 Study Results

New Retina Radio by Eyetube
25/10/2022 10 min
AAO '22: GATHER2 Study Results

Listen "AAO '22: GATHER2 Study Results"

Descargar episodio

Episode Synopsis

Researchers in the second pivotal study evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio) for the treatment of geographic atrophy have released 1-year results. New Retina Radio spoke with Arshad Khanani, MD, MS, about the GATHER2 study findings. How did the study results compare to the GATHER1 conclusions—and might the company move forward with a regulatory filing?

More episodes of the podcast New Retina Radio by Eyetube

Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR 23/10/2025
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care 10/10/2025
The Nuts and Bolts of GA Therapy: The Opening Sessions 09/10/2025
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision 02/10/2025
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation 02/10/2025
Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations 02/10/2025
Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention 02/10/2025
New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab 26/09/2025
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR 04/09/2025
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders 21/08/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA